纤维蛋白原和血小板高反应性与冠状动脉支架内再狭窄的相关性被引量：1

Relation amomg fibrinogen,high platelet reactivity and coronary in-stent restenosis

下载PDF

导出

摘要目的:探讨经皮冠脉介入术(PCI)后患者的纤维蛋白原和血小板高反应(HPPR)与支架内再狭窄(ISR)的相关性。方法:回顾性分析2011年9月至2012年8月收治的191例PCI术后患者的临床资料,其中150例无ISR(对照组)、41例ISR(试验组),对比两组患者年龄、性别、BMI、纤维蛋白原、血小板聚集功能以及植入支架数目等指标。结果:对照组和试验组患者的年龄、BMI、高脂血症、纤维蛋白原及HPPR比较,差异均有统计学意义(P<0.05)。纤维蛋白原水平和HPPR是ISR的独立危险因素(P<0.05)。结论:纤维蛋白原和HPPR可作为ISR的预测因素。 Objective：To investigate the correlation among the level of fibrinogen, high platelet reactivity （HPPR） and in-stent restenosis （ISR） in patients following percutaneous coronary intervention （PCI）. Methods： We did a retrospective analysis on the clinical profiles of 191 patients who underwent PCI between September 2011 and August 2012. Patients were allocated to nil ISR （control group, n = 151 ） or ISR group （experimental group, n =41 ） for subsequent comparison on the age, sex, BMI, fibrinogen, platelet aggregation and the number for stent placement. Results： There was a significant between-group difference in the age, sex, BMI, fibrinogen, the incidence of hyperlipidemia and HPPR （ all P 〈 0.05 ）. The level of fibrinogen and HPPR are independent risk factors of ISR （ both P 〈 0.05 ）. Conclusion： The level of fibrinogen and HPPR are predictive factors of ISR.

作者范怀周程映雪张县华

机构地区汕头市潮南民生医院心内科汕头市潮南民生医院超声科

出处《广州医学院学报》 2013年第5期34-36,共3页 Academic Journal of Guangzhou Medical College

关键词纤维蛋白原高血小板反应性支架内再狭窄 fibrinogen high platelet reactivity in-stent restenosis

分类号 R541 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献12

1Gurbel PA,Bliden KP,Hiatt BL,et al.Clopidogrel for coronary stenting:response variability,drug resistance,and the effect of pretreatment platelet reactivity[J].Circulation,2003,107(23):2908-2913.
2Gurbel PA,Samara WM,Bliden KP.Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting:implications for thrombotic events and restenosis[J].Platelets,2004,15(2):95-99.
3Bonello L,Tantry US,Marcucci R,et al.Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate[J].J Am Coll Cardiol,2010,56(12):919-933.
4Kim IS,Jeong YH,Kang MK,et al.Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay[J].J Thromb Thrombolysis,2010,30(4):486-495.
5Jeong YH,Kim IS,Park Y,et al.Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day:results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study[J].JACC Cardiovasc Interv,2010,3(7):731-741.
6Lima LM,Carvalho M,Sousa MO.Plasminogen and fibrinogen plasma levels in coronary artery disease[J].Rev Bras Hematol Hemoter,2012,34(4):298-301.
7Ferreiro JL,Homs S,Berdejo J,et al.Clopidogrel pretreatment in primary percutaneous coronary intervention:Prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery[J].Thromb Haemost,2013,110(1).
8Vadasz D,Sztriha L K,Sas K,et al.Aspirin and clopidogrel resistance:possible mechanisms and clinical relevance.Part II:Potential causes and laboratory tests[J].Ideggyogy Sz,2013,66(1-2):15-22.
9翟东东,王斌.血栓弹力图测定的经皮冠状动脉介入治疗患者血小板高反应性及其临床意义[J].中国介入心脏病学杂志,2008,16(5):259-263. 被引量：12
10Gurbel PA,Bliden KP,Samara W,et al.Clopidogrel effect on platelet reactivity in patients with stent thrombosis:results of the CREST Study[J].J Am Coll Cardiol,2005,46(10):1827-1832.

二级参考文献30

1Swallow RA, Agarwala RA, Dawkins KD, et al. Thromboelastography : potential bedside tool to assess the effects of antiplatelet therapy? Ptatelets,2006,17:385-392.
2Kevin P, Joseph D, Udaya ST, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention. J Am Coll Cardiol,2007, 49:657-666.
3Bliden KP, Tantry U, Zaman K, et al. High platelet reactivity is a risk factor for post-discharge ischemic complications following elective coronary stenting. J Am Coil Cardiol, 2005,47:45B.
4Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coil Cardiol,2005 ,46 :1705-1709.
5Agarwal S, Coakely M, Reddy K, et ah Quantifying the effect of antiplatelet therapy : a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry. Anesthesiology, 2006, 105:676-683.
6Bochsen L, Wiinberg B, Kjelgaard-Hansen M, et al. Evaluation of the TEG platelet mapping? assay in blood donors. Thromb J, 2007, 5 : 1-5.
7Craft RM, Chavez J J, Bresee SJ, et al. A novel modification of the Thrombelastograph assay, isolating platelet function, correlated with optical platelet aggregation. J Lab Clin Med, 2004,143 : 301-309.
8Lev EI, Patel RT, Maresh KJ. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention : the role of dual drug resistance. J Am Coil Cardiol, 2006, 47 :27- 33.
9Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coil Cardiol,2004,43 : 1122-1126.
10Ridker PM, Cook NR, Lee IM, et al. A randomized trial of lowdose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med, 2005,352:1293-1304.